Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its products consist of five pre-clinical or clinical-trial stage drug candidates developed by it and designed to target immune response, and two therapeutic agents developed by its Enviro Therapeutics, Inc. (Enviro) subsidiary and designed to increase anti-tumor response in conjunction with cancer therapies by addressing resistance to these agents. Its product portfolio includes a variety of technologies licensed by its Enviro subsidiary and consists of compositions and methods for treating diseases and conditions by targeting CD105 and depleting mitochondrial DNA from the circulation. Its products include KROS 101, 102, 201, 301, 401, ENV 105 and 205.